Dec 09, 2020 04:20 PM EST
Pfizer Inc. announced that the Food and Drug Association (FDA) granted priority review to its biologics license application that seeks approval for its 20-valent pneumococcal conjugate vaccines for adults.
According to NASDAQ, the FDA granted priority review, which is expected to release in June 2021. Pfizer's v includes 13 serotypes in its well-known 13-valent pneumococcal conjugate vaccine, seven serotypes, and Prevnar 13.
Meanwhile, Merck (MRK) is in the process of developing a 15-valent pneumococcal conjugate vaccine candidate in late-stage studies. Merck's phase III clinical development program includes 16 late-stage studies that will evaluate the vaccine candidate in different populations who are at a higher risk for pneumococcal disease.
This year, Pfizer's shares rose to 8.6% compared with the industry's 2.8% increase. The share price increased primarily because of Pfizer and its Germany-based partner BioNTech's rapid development and regulatory plans for its COVID-19 vaccine candidate.
In the United Kingdom and Bahrain, the COVID-19 two-shot vaccine was approved for emergency use this month. The drugmaker giant also filed for emergency use in the U.S., India, and E.u. Besides, the companies initiated rolling submissions with Australia, Japan, and Canada regulatory agencies.
Readl also: Why a COVID-19 Vaccine Won't Be a Magic Bullet for the Economy Any Time Soon
In the past month, Pfizer stock increased to more than 20% on the enthusiasm that it will be the first drugmaker to bring scientifically validated COVID-19 vaccine worldwide. Pfizer's commercialization efforts also generated tens of billions of dollars in potential revenue, as per The Motley Fool via MSN.
Many investors are aiming to get rich off of Pfizer's stock with its shares gaining momentum. However, Pfizer and BioNTech's messenger RNA coronavirus vaccine achieved 95% efficacy in late-stage last month.
Initially, Pfizer's COVID-19 vaccine was initiated to patients in the U.K. and is awaiting EUA by the FDA and approval by the European Medical Agency. Pfizer is expected to make 50 million doses of COVID-19 vaccines and another 1.3 billion by the end of 2021.
There is a lot of revenue potential at the price tag of $19.5. Aside from that, Pfizer; score operations perform handsomely, as per Motley Fool. On November 16, the drugmaker giant completed the generic drug business Upjohn's spin-off to form Viatris.
This year, Upjohn's revenue dropped by 18% for more than a year as the FDA approved a record number for generics as an initiative to crack down high drug pricing. Pfizer's core business is currently consisted of brand name oncological drugs, anti-infectious disease treatments, cardiovascular treatments,, and biosimilars.
During its biopharma sales grew by 4% compared to 2019 with $10.2 billion. For the full year, the new Pfizer expects to bring in $42.4 billion in sales and $2.38 in earnings per share. The company projects can grow its revenue to more than 6% yearly from now through 2025.
Read also: Monulparivir: New Antiviral Drug That Completely Suppresses the Transmission of the COVID-19 in 24 Hours
And the world of NFTs expands far beyond art and collectibles. A new era of tokenized digital assets is being created using the blockchain. Here are seven unique NFT use cases that the interested investor should know.
However, there are some simple steps that anyone can take which will help to improve their performance when it comes to trading foreign exchange markets. Here are ten small things that can make a big difference in your FX trading success.
o prevent significant losses, risk management expertise is essential. His adage, "Rule No. 1: Never lose money," has become a stock market classic. Never forget Rule No. 1; this is Rule No. 2. This practice is followed by even the most successful investor, Warren Buffett, who advises others to follow suit.
One of the significant advancements is shifting the payment operations for remote workers. If the compliances are not met, it may lead to severe legal complications. The owner and organization may be held labially separately. The remote working lifestyle continuously grows and is a testament to becoming an endless working mode. Today we discuss components for payroll for remote workers
BRG International Founder Matias Alem had recognized this fact for a few years. So he remodeled his real estate brokerage into something completely new to solve the problem for his jet-setting international client base.
Ryan Early, hailed as 'Farmer Ryan' among sustainable agriculture experts, is a busy man. He has a laundry list of companies to his name, including Blue-Green Ventures, the company behind the revolutionary product, Blue MagicTM, a non-toxic and eco-sustainable pest preventative product using his patented BiomeMax TM Pheromonal Replication Technology.
Investor, financier, and expert in both cryptocurrencies and blockchain technology, Joy Mbanugo is the go-to in the sector. She has vast experience and knowledge across tax services, auditing, business operations, financial analysis, capital markets, and other specializations.
When Nick Collins was just 14 years old, he started his first business, which included around-the-clock phone calls and numerous questions from his parents. In fact, he began building his stout portfolio in the seventh grade by doing web design, incorporating creative content with brand strategies and plugging in a then-fledgling tech Flash.
Barry Gabster is the founder of InitiateU and is a leading proponent of the marketing mailer revolution, having already taken his company to 10x growth in 2021, alone. In fact, the exponential growth has seen the company rise from $800K-$8.5M just on word-of-mouth referrals.